The drug SI-B001 represents an exciting advance in the treatment of relapsed multiple myeloma. The first-in-class antibody directly interacts with BCMA within myeloma malignancies, leading to antibody-dependent cell cytotoxicity while promoting anti-tumor patient's activity. Preliminary investiga